Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket
Details
The document's own metadata, straight from the source system.
- Title
- Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket
- Posted
- Oct 27, 2015
- Comment period
- Oct 27, 2015 – Feb 22, 2050
- FR Doc
- 2015-27271
- Topics
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Uncheck an issue to choose another.
| Organization | Bulk compounding substances | Individualized patient care | Compounded medication benefits | Patient access to compounded medications | Patient choice and access |
|---|---|---|---|---|---|
state-licensed 503A compounding pharmacy BusinessSupport A state-licensed 503A compounding pharmacy is submitting a nomination for the bulk drug substance TB-500. | · | · | · |
5 organization-typed comments could not be identified.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- Jan 16, 2025Comment from XeCare LLCSupportBusiness📎 Attachment
XeCare LLC is submitting formal nominations for several bulk drug substances, including Ashwagandha root extract, Eurycoma Longifolia root extract, Fenugreek seed, Saffron, Berberine Hydrochloride, and Menaquinone-4, to be included on the FDA's 503A Bulks List. The company provides specific extraction methods, constituent concentrations, and clinical evidence to support the inclusion of these substances for treating various conditions.
Read comment → - Oct 18, 2023Ian TarasOpposeIndividual
The commenter argues against the FDA's classification of various peptides as substances that may cause harm. They advocate for the continued use of these peptides for medical and performance purposes, arguing that they are safer alternatives to synthetic drugs.
Read comment → - Oct 17, 2023Debra RobinsonOpposeIndividual
The commenter, an individual, opposes the proposed action by arguing that the FDA should not restrict access to various peptides. They contend that these substances are beneficial for treating conditions where pharmaceutical drugs fail and that removing them limits patient and physician choice.
Read comment → - Oct 17, 2023J ROpposeIndividual
The commenter expresses frustration and distrust regarding the FDA's lack of transparency concerning safety concerns for peptides. They argue that the regulatory action appears to be motivated by financial interests rather than public safety, specifically targeting natural substances that cannot be patented.
Read comment → - Oct 8, 2023Comment from Iron DPCSupportIndividual
A healthcare practitioner argues that the FDA's current restrictions on peptides hinder medical innovation and patient care. They advocate for allowing peptides to be compounded and prescribed, citing their success in treating various conditions and improving patient quality of life.
Read comment → - Oct 7, 2023Jackie KeckOpposeIndividualRead comment →
- Apr 29, 2019Comment from Melissa CohenOpposeIndividualRead comment →
- Apr 2, 2019Comment from Roscoe RossiOpposeIndividual
A patient expresses strong opposition to the proposed action, stating that removing certain substances from the list of compoundable medicines would cause them severe physical harm. They specifically cite curcumin as a substance they rely on for health benefits and argue that its removal would lead to life-threatening complications.
Read comment → - Feb 25, 2019Comment from JustinaOpposeIndividualRead comment →
- Feb 23, 2019Comment from AnonymousOpposeIndividualRead comment →
